Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciproca...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
International Scientific Literature, Inc.
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560700/ |